Charles River Laboratories International ... The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $9.5 billion by ...

Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in ...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday ...

Riverwater Partners Sustainable Value Strategy highlighted stocks like Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter 2024 investor letter. Charles River ...